ArticleFrontiers in neurology2022
Immune-Inflammatory Biomarkers Predict Cognition and Social Functioning in Patients With Type 2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: A 1-Year Follow-Up Study.
Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Biofluid Biomarkers of Cognitive Functioning in Bipolar Disorder: A Systematic Review by the Targeting Cognition and Older-Age Bipolar Disorder ISBD Task Forces.Bipolar disorders · 2026Pooled it
- Association Between Inflammatory Markers and Cognitive Function in Adults With Bipolar Disorder: A Systematic Review.Acta psychiatrica Scandinavica · 2026Pooled it
- Relationships Between Immune-Inflammatory Features and Social Cognitive Impairments in Patients With Schizophrenia Spectrum Disorders: A Systematic Review.Brain and behavior · 2025Pooled it
- Sex differences in higher-order cognition in schizophrenia and unaffected first-degree relatives: a longitudinal, family study.European archives of psychiatry and clinical neuroscience · 2026Article
- Linking peripheral low-grade inflammation and blood-cerebrospinal fluid barrier leakage in schizophrenia spectrum disorders - A retrospective analysis.Brain, behavior, & immunity - health · 2026Article
- Linking sleep microstructure, blood markers of inflammation and metabolism, and cognition: mediation analysis in the osteoporotic fractures in men study.GeroScience · 2026Article
- Neuroimmune Interactions in Stress and Depression: Exploring the Molecular and Cellular Mechanisms within the Neuroinflammation-depression Nexus.Current medicinal chemistry · 2026Review
- Analytical Biomarkers for Inflammation Status Monitoring of Psychotropic and Antiepileptic Drugs.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Biological mechanism and functional verification of key genes related to major depressive disorder and type 2 diabetes mellitus.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Article
- Specific immune-inflammatory profiles and neurocognitive deficits predict illness trajectories in people with type 2 diabetes mellitus or psychiatric disorders.Brain, behavior, & immunity - health · 2025Article
- Article
- Major depressive disorder is associated with mitochondrialWorld journal of psychiatry · 2024Article
- Association between olfactory function and metabolic syndrome in bipolar disorder patients: a cross-sectional study.BMC psychiatry · 2024Article
- Inflammatory Biomarkers, Cognitive Functioning, and Brain Imaging Abnormalities in Bipolar Disorder: A Systematic Review.Clinical neuropsychiatry · 2024Review
- Plasma IGFBP-3 and IGFBP-5 levels are decreased during acute manic episodes in bipolar disorder patients.Frontiers in pharmacology · 2024Article
- Connecting Neurobiological Features with Interregional Dysconnectivity in Social-Cognitive Impairments of Schizophrenia.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic, low-grade immune-inflammatory activity, together with social and neurocognitive performance deficits are a transdiagnostic trait of people suffering from type 2 diabetes mellitus (T2DM) and severe mental illnesses (SMIs), such as schizophrenia (SZ), major depressive disorder (MDD), and bipolar disorder (BD). We aimed to determine if immune-inflammatory mediators were significantly altered in people with SMIs or T2DM compared with healthy controls (HC) and whether these biomarkers could help predict their cognition and social functioning 1 year after assessment. Methods: We performed a prospective, 1-year follow-up cohort study with 165 participants at baseline (TB), including 30 with SZ, 42 with BD, 35 with MDD, 30 with T2DM, and 28 HC; and 125 at 1-year follow-up (TY), and determined executive domain (ED), global social functioning score (GSFS), and peripheral blood immune-inflammatory and oxidative stress biomarkers. Results: Participants with SMIs and T2DM showed increased peripheral levels of inflammatory markers, such as interleukin-10 ( Limitations: Participants' treatment, as usual, was continued without no specific interventions; thus, it was difficult to anticipate substantial changes related to the psychopharmacological pattern. Conclusion: People with SMIs show significantly increased levels of peripheral immune-inflammatory biomarkers, which may contribute to the neurocognitive and social deficits observed in SMIs, T2DM, and other diseases with systemic immune-inflammatory activation of chronic development. These parameters could help identify the subset of patients who could benefit from immune-inflammatory modulator strategies to ameliorate their functional outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.